TICKERNERD
Menu
CLDICLDIHealthcare · Biotechnology

CLDI Stock Forecast: Calidi Biotherapeutics, Inc. Price Predictions for 2026-2027

Last close, 31 July 2026
$1.64

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 1 Aug 2026 — in the weakest quartile.

Market cap
$31.7M
Ticker Nerd rank
23 / 100
Median analyst target
—
Analysts covering
—
Ticker Nerd rank

CLDI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Calidi Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
23 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
99
Accruals
91
Issuance
55
Growth
41
Revisions
25
Volatility
25
Quality
15
Value
7
Momentum
1

Size (99): Smaller than most of the companies we track.

Momentum (1): The shares have been drifting down relative to others.

The rank is the raw material. Whether the rules would actually own Calidi Biotherapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

CLDI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CLDI, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 June 2024Ladenburg ThalmannInitiatesBuy—
15 May 2024BairdMaintainsOutperform—
21 Mar 2024BairdMaintainsOutperform—
21 Mar 2024HC Wainwright & Co.MaintainsBuy—
22 Nov 2023HC Wainwright & Co.InitiatesBuy—
9 Oct 2023BairdInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

CLDI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Calidi Biotherapeutics, Inc. (CLDI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.8×

Cheaper than 70% of US stocks

Price / sales
—
Price / book
0.2×

Cheaper than 88% of US stocks

EV / EBITDA
0.1×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−312.4%

Higher than 4% of US stocks

Return on assets
−98.2%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CLDI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CLDICalidi Biotherapeutics, Inc.$31.7M
23
SLXNSilexion Therapeutics Corp.$2.0M
37
VRAXVirax Biolabs Group Ltd.$2.1M
12
CDTCDT Equity, Inc.$1.8M
14
MBRXMoleculin Biotech, Inc.$2.1M
11
AZTRAzitra, Inc.$2.1M
29
OGENOragenics, Inc.$2.2M
19
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CLDI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest CLDI news & analysis

Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference

GlobeNewsWire · 27 July 2026positive

Calidi Biotherapeutics presented new data on its CLD-401 program and its in situ T-cell engager program at the American Association for Cancer Research Drug Discovery and Development Conference in Boston on July 23, 2026.

Why it matters — The presentation highlights progress in Calidi's pipeline, specifically the CLD-401 program expected to enter the clinic in the first quarter of 2027.

FAQ

Frequently asked questions about CLDI stock

How does Ticker Nerd's model rank CLDI?

As at 1 Aug 2026, Calidi Biotherapeutics, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).

What is the CLDI stock forecast for 2030?

No analyst covering Calidi Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLDI are extrapolating price history, which says nothing about the business.

What does Calidi Biotherapeutics, Inc. do?

Calidi Biotherapeutics Inc. is a biotechnology company focused on developing innovative oncolytic virus-based immunotherapies for cancer treatment.

What is the latest news on CLDI?

The most recent item we track (GlobeNewsWire, 27 July 2026): "Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference". Calidi Biotherapeutics presented new data on its CLD-401 program and its in situ T-cell engager program at the American Association for Cancer Research Drug Discovery and Development Conference in Boston on July 23, 2026.

Company

About Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics Inc. is a biotechnology company focused on developing innovative oncolytic virus-based immunotherapies for cancer treatment. Oncolytic viruses are engineered to selectively infect and destroy cancer cells while stimulating immunity against tumors. Calidi's primary goal is to harness the power of viral-based therapies to provide novel solutions for patients with unmet medical needs in oncology. The company is pioneering the development of combination therapies that integrate these oncolytic viruses with stem cell technology to enhance the delivery and efficacy of treatments. This approach positions Calidi Biotherapeutics as a key player within the biotech sector, impacting the broader healthcare and pharmaceutical industries. Established to spearhead advancements in cutting-edge cancer treatments, Calidi operates within a competitive yet rapidly growing market segment committed to improving patient outcomes and broadening the therapeutic landscape for cancer care. By capitalizing on advanced viral and cellular methodologies, Calidi Biotherapeutics aims to contribute significantly to the next generation of cancer therapies.

CEO Dr. Eric E. Poma Ph.D. · 29 employees · United States · https://www.calidibio.com